Exosomes for Hair and Skin: What They Are and What the Evidence Shows
Doctor-led discussion of topical extracellular-vesicle products used as an adjunct in selected scalp and skin-rejuvenation plans. The underlying biology is genuine and actively researched, but clinical evidence is early and varies substantially by product and protocol.
Aquila does not describe exosomes as a proven cure for hair loss, an epigenetic “reset,” a stem-cell treatment, or a guaranteed way to reactivate dormant follicles.
This page explains the science plainly, sets out what is and is not currently supported for hair growth and skin rejuvenation, and is direct about the regulatory position — because that is information patients are entitled to have before spending money.
Exosomes at a glance
| What they are | Nanoscale extracellular vesicles, roughly 30–150 nm, released by cells and carrying proteins, lipids and nucleic-acid cargo |
|---|---|
| What they are not | Not stem cells, not living cells, and not a source of new cells. They are signalling packages, not building blocks |
| Common sources | Cultured mesenchymal stem cells (often umbilical-cord derived), platelets, adipose tissue or plant sources — which are not equivalent |
| How used at Aquila | Topically, as an adjunct after selected procedures — not as a standalone therapy and not as an injected biologic |
| Discussed for | Adjunctive support in hair-loss plans and post-procedure skin rejuvenation |
| Evidence status | Laboratory and early clinical work is encouraging. Controlled human trials remain small, few and heterogeneous |
| Regulatory status | No exosome product is approved as a therapeutic anywhere. Regulators have issued repeated warnings about unapproved products |
| Not a substitute for | Diagnosis, minoxidil, 5-alpha reductase inhibitors, established devices, or hair transplantation where indicated |
| Where | Aquila Medical Center, 160 Robinson Road, #05-01 SBF Centre Medical Suites, Singapore 068914 |
What are exosomes?
Exosomes are small extracellular vesicles released by cells. They can carry proteins, lipids and nucleic-acid cargo involved in cell-to-cell signalling. In research settings, extracellular vesicles are being studied in wound healing, inflammation and hair-follicle biology.
The concept is best understood as messaging rather than replacement. Cells package signalling molecules inside a membrane-bound vesicle and release it; neighbouring cells take it up and respond to the cargo. The therapeutic idea is that vesicles from cells with useful signalling behaviour might influence recipient tissue — prompting fibroblasts to behave more actively, or modulating the inflammatory environment around a hair follicle.
One correction matters more than any other here: exosomes are not stem cells, and a treatment using them is not a stem-cell treatment. They contain no nucleus, cannot divide and do not become new tissue. Clinics that blur this distinction are describing something the product cannot do.
Important: “Exosome” is not one standardized medicine. Source cells, manufacturing, purification, concentration, cargo, storage and route of application can differ substantially between products.
This heterogeneity is not a minor technicality. The international research community has published formal standards precisely because verifying what a given vial actually contains is difficult even in a well-equipped laboratory. Two products both labelled “exosomes” can differ in source, purity, vesicle concentration and cargo — so evidence generated for one tells you very little about another.
How they are proposed to work
Signalling, not substitution
The vesicle delivers cargo that may influence how recipient cells behave. Nothing is being replaced or regrown from the product itself.
Modulating inflammation
Much of the laboratory interest concerns damping inflammatory signalling, which is relevant both to scalp conditions and to post-procedure recovery.
Influencing the hair cycle
Preclinical work has examined pathways governing the transition into and length of the growth phase, which is the mechanism most cited for hair applications.
Supporting wound healing
The post-laser or post-microneedling context is where topical use is most often proposed — supporting recovery rather than driving the result.
Fibroblast signalling
For skin rejuvenation, the proposed mechanism involves prompting fibroblast activity relevant to dermal matrix quality.
The honest caveat
Nearly all of the above is mechanism rather than demonstrated clinical outcome. A plausible pathway is not the same as a proven result.
Absorption is a further open question. Intact skin is an effective barrier to particles of this size, which is why topical use is generally proposed immediately after a procedure that has temporarily disrupted that barrier. How much material actually reaches viable tissue, and in what functional state, is not well established.
Exosomes for hair growth
Laboratory and early clinical studies suggest extracellular-vesicle preparations may influence pathways involved in follicular growth and inflammation. However, human studies remain relatively small and heterogeneous, and commercial products are not interchangeable.
It is therefore more accurate to describe topical exosome products as an emerging adjunct rather than established first-line therapy for androgenetic alopecia, alopecia areata or telogen effluvium.
Put in context: the treatments with genuine randomised evidence for pattern hair loss are topical and oral minoxidil, 5-alpha reductase inhibitors in appropriate patients, low-level laser therapy, and surgical restoration where the pattern is stable. Exosome products sit outside that group. A patient who has not yet tried the evidence-based options is almost always better served by starting there.
The realistic role, if any, is additive — used alongside established treatment and a correct diagnosis, typically applied after a procedure that has opened a delivery window. It should not delay investigation, and it should not be the centrepiece of a hair-loss plan.
Exosomes for skin rejuvenation
The second common application is topical use immediately after laser resurfacing, microneedling or radiofrequency microneedling, with the aim of supporting recovery and enhancing the result of the underlying procedure.
Reported and proposed benefits centre on reduced post-procedure redness and downtime, improved comfort, and possible additive effect on skin quality. Small open-label studies and case series report favourable impressions, but controlled data separating the exosome contribution from the effect of the procedure itself are limited — and that separation is the entire question.
This is worth being clear-eyed about. Laser resurfacing and microneedling produce real improvements on their own. When a good result follows a procedure plus a topical product, attributing the improvement to the product requires a controlled comparison that mostly has not been done at the quality needed.
A reasonable position: if you are having the procedure anyway and choose to add a topical adjunct after an informed discussion of cost and evidence, that is a defensible personal decision. Paying substantially for the adjunct on the expectation that it, rather than the procedure, delivers the result is not well supported.
Diagnosis remains the foundation
Pattern hair loss, telogen effluvium, alopecia areata, scarring alopecia and inflammatory scalp disease require different management. An adjunctive topical product should not delay investigation or evidence-based treatment.
Where appropriate, established options may include medical therapy, low-level light therapy, selected topical delivery approaches or hair transplantation depending on diagnosis and severity.
The same principle applies to skin. Pigmentation, texture, laxity, redness and scarring are different problems with different answers, and no adjunct substitutes for identifying which one you actually have.
Topical use versus injection
Route matters. Applying a topical extracellular-vesicle product after a scalp procedure is not equivalent to injecting a biologic product into tissue. Safety, sterility and regulatory considerations differ.
Aquila uses these products topically. Injection of exosome preparations sits in a materially different regulatory category and carries different risks, including infection from inadequately characterised preparations.
Patients should not assume that all “exosome therapy” described online has the same evidence, the same route or the same regulatory standing. Product-specific information and route of administration should be reviewed during consultation.
The regulatory position, stated plainly
There are currently no exosome products approved as therapeutics by major regulators. Regulatory agencies have issued repeated public safety communications about unapproved exosome products marketed for medical conditions, and enforcement activity against manufacturers and distributors has increased through 2024 to 2026. Reported adverse events associated with poorly characterised preparations include serious infections.
An important nuance: marketing an exosome product as a treatment for a condition — hair loss included — is itself a therapeutic claim, which is what regulators treat as converting a “cosmetic” product into an unapproved drug. This is why our position is that these products are discussed as adjuncts and never presented as a therapy for a diagnosed condition.
None of this means the underlying science is worthless. It means the field is at the stage where honest practice involves stating uncertainty rather than concealing it, and where a patient should be told the regulatory status before deciding, not after.
Questions worth asking any clinic: what is the source material, is it topical or injected, what is the regulatory status of that specific product, what evidence exists for that product rather than for exosomes in general, and what would the plan be without it?
Risks and uncertainties
Potential issues include irritation, contact reactions, infection risk if used with procedures that disrupt the skin barrier, contamination or variability in poorly characterized products, and disappointment if expected hair regrowth does not occur.
Cost deserves naming as a real consideration. These products are expensive, and money spent on an adjunct with limited evidence is money not spent on treatments with strong evidence. For a patient with a fixed budget and untreated pattern hair loss, that trade-off is a genuine clinical issue rather than a purely financial one.
Patients with active scalp or skin infection, inflammatory flares, known sensitivity to product components, or who are pregnant or breastfeeding should discuss suitability before any adjunctive product is used.
Rapid, patchy, painful or scarring hair loss needs medical assessment. These patterns should not be treated empirically with cosmetic adjuncts.
Frequently asked questions
Are exosomes proven to regrow hair?
Not to the same standard as established hair-loss therapies. Early studies are promising, but evidence is still limited and product-specific.
Are all exosome products the same?
No. Source, manufacturing, purification, concentration and formulation can differ substantially, so evidence for one product tells you little about another.
Are exosomes the same as stem cells?
No, and this is the most important correction. Exosomes are membrane-bound signalling packages released by cells. They contain no nucleus, cannot divide and do not become new tissue.
Can exosomes replace minoxidil, anti-androgen therapy or hair transplantation?
Not generally. Their role, if any, is adjunctive and depends on the diagnosis and treatment plan.
Can they treat scarring alopecia?
Scarring alopecia requires prompt diagnosis and condition-specific medical treatment. Cosmetic adjuncts should not delay care.
Are exosome products approved by regulators?
No exosome product is approved as a therapeutic by major regulators, and agencies have issued repeated warnings about unapproved products marketed for medical conditions.
Why are they applied after a laser or microneedling procedure?
Because intact skin is an effective barrier to particles of this size. Application is proposed immediately after a procedure that has temporarily disrupted that barrier, though how much material reaches viable tissue is not well established.
Do exosomes help skin rejuvenation?
Small open-label studies report favourable impressions of reduced redness and improved recovery, but controlled data separating the exosome contribution from the effect of the procedure itself are limited.
Is injection better than topical application?
Injection sits in a materially different regulatory category and carries different risks including infection from inadequately characterised preparations. Aquila uses these products topically.
Where do exosomes come from?
Commonly from cultured mesenchymal stem cells, often umbilical-cord derived, or from platelets, adipose tissue or plant sources. These are not equivalent, and the source is a fair question to ask.
Are they safe?
Topical use on selected patients is generally well tolerated, but the honest answer is that safety data for poorly characterised preparations are limited, and serious infections have been reported with non-validated products.
Should I choose exosomes over a treatment with better evidence?
Generally no. If evidence-based options for your diagnosis have not been tried, starting there is usually the better use of both time and money.
How many sessions would be involved?
There is no established protocol, which is itself informative. Any schedule offered is based on product recommendation rather than robust comparative evidence.
Will I see results immediately?
Any post-procedure improvement in redness or comfort would be early, while claimed effects on hair or skin quality would develop over months — and would be difficult to separate from the procedure itself.
Can I have exosome treatment while pregnant or breastfeeding?
Elective adjunctive products are conventionally deferred, particularly where safety data are absent rather than reassuring.
What should I ask before agreeing to treatment?
What the source material is, whether it is topical or injected, the regulatory status of that specific product, what evidence exists for that product specifically, and what the plan would be without it.
Is it worth the cost?
That is a personal judgement, but it should be made knowing the evidence is early. Money spent on an adjunct is money not spent on treatments with stronger evidence, which matters on a fixed budget.
Does Aquila inject exosomes?
No. These products are used topically as an adjunct after selected procedures, not injected.
Is exosome treatment claimable under MediSave or insurance in Singapore?
Aesthetic treatment for cosmetic indications is generally not claimable under MediSave or most private insurance policies. Check directly with your insurer.
Where is Aquila Medical Center?
Aquila Medical Center is at 160 Robinson Road, #05-01 SBF Centre Medical Suites, Singapore 068914, in the CBD, a short walk from Tanjong Pagar, Shenton Way and Telok Ayer MRT stations.
Selected references and further reading
- Jafarzadeh A, et al. Effectiveness of regenerative medicine for skin lightening and rejuvenation: a systematic review of extracellular vesicles and conditioned media. Stem Cell Res Ther. 2025.
- Kinoshita-Ise M, et al. Recent advances in the etiopathogenesis, diagnosis and management of hair loss diseases.
- Androgenetic Alopecia. StatPearls, NCBI Bookshelf.
- Comparative effectiveness of low-level laser therapy for androgenetic alopecia: systematic review and meta-analysis.
- American Academy of Dermatology. Hair loss: diagnosis and treatment.
- US FDA. Consumer alert on regenerative medicine products including stem cells and exosomes.
This page is educational and does not replace an individual assessment. Exosome and extracellular-vesicle products are discussed here as adjuncts with early evidence, not as approved therapies. Results vary between individuals and no outcome can be guaranteed. Content reviewed by the medical team at Aquila Medical Center, Singapore. Last reviewed: 26 August 2026.
Doctor-led hair and skin assessment
The useful question is not whether an exosome product sounds regenerative, but whether it adds meaningful value to the treatment plan for a correctly diagnosed hair or skin condition.
Aquila Medical Center is located at 160 Robinson Road, #05-01 SBF Centre Medical Suites, Singapore 068914, a short walk from Tanjong Pagar, Shenton Way and Telok Ayer MRT stations. If an established treatment would serve you better than an adjunct, we will say so.